Symptom-onset treatment for women with premenstrual dysphoric disorder

Journal of Clinical Psychopharmacology

Volumn 26, Issue 2, 2006, Pages 198-202

  Yonkers, Kimberly A ^a   Holthausen, Gretchen A ^a   Poschman, Karalee ^a   Howell, Heather B ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY; NAUSEA; NON INVASIVE MEASUREMENT; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MENSTRUAL CYCLE; PAROXETINE; PATIENT COMPLIANCE; PREMENSTRUAL SYNDROME; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS;

EID: 33646684711     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000203197.03829.ae     Document Type: Article

References (29)

1. Sternfeld B, Swindle R, Chawla A, et al. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol. 2002;99:1014-1024.
2. Pearlstein TB, Yonkers KA, Fayyad R, et al. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J Affect Disord. 2005;85:275-282.
3. Dimmock PW, Wyatt KM, Jones PW, et al. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet. 2000;356:1131-1136.
4. Yonkers KA, Clark RH, Trivedi MH. The psychopharmacological treatment of nonmajor mood disorders. In: Rush AJ, ed. Mood Disorders: Systematic Medication Management. Modern Problems of Pharmacopsychiatry. Vol. 25. Basel, Switzerland: Karger Publishers; 1997:21.
5. Cohen LS, Miner C, Brown EW, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol. 2002;100:435-444.
6. Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry. 1997;58:399-402.
7. Jermain DM, Preece CK, Sykes RL, et al. Luteal phase sertraline treatment for premenstrual dysphoric disorder: results of a double-blind, placebo-controlled, crossover study. Arch Fam Med. 1999;8:328-332.
8. Landen M, Sorvik K, Ysander C, et al. A placebo-controlled trial exploring the efficacy of paroxetine for the treatment of premenstrual dysphoria. Presented at: the American Psychological Association Meeting; 2002; Philadelphia, PA.
9. Miner C, Brown E, McCray S, et al. Weekly luteal phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther. 2002;24:417-433.
10. Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology. 1993;9:133-145.
11. Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol. 1998;18:390-398.
12. Young SA, Hurt PH, Benedek DM, et al. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry. 1998;59:76-80.
13. Halbreich U, Bergeron R, Yonkers KA, et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2002;100:1219-1229.
14. Steiner M, Korzekwa M, Lamont J, et al. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull. 1997;33:771-774.
15. Gee M, Bellew K, Holland F, et al. Luteal phase dosing of paroxetine controlled-release is effective in treating premenstrual dysphoric disorder (PMDD). Presented at: the American Psychological Association Meeting; 2003; San Francisco, CA.
16. Freeman EW, Sondheimer SJ, Sammell MD, et al. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J Clin Psychiatry. 2005;66:769-773.
17. Endicott J , Harrison W. The Daily Record of Severity of Problems. New York: Department of Research Assessment and Training, New York State Psychiatric Institute; 1990.
18. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini International Neuropsychiatrie Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22-33. [quiz, 34-57].
19. Steiner M, Haskett RF, Carroll BJ. Premenstrual tension syndrome: the development of research diagnostic criteria and new rating scales. Acta Psychiatr Scand. 1980;62:177-190.
20. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS) psychometric properties. Psychol Med. 1996;26:477-486.
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
22. Guy W. Clinical global impressions. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Vol. 217. Rockville, MD: National Institute of Mental Health; 1976:6.
23. Yonkers KA, Pearlstein TB, Fayyad R, et al. Luteal phase treatment of premenstrual dysphoric disorder (PMDD) improves symptoms that continue into postmenstrual phase. J Affect Disord. 2005;85(3):317-321.
24. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment: double-blind, placebo-controlled trial. Br J Psychiatry. 2000;176:363-368.
25. Grizzle J. The two-period change-over design and its use in clinical trials. Biometrics. 1965;21:467-480.
26. SAS System [computer program]. Version 9.1. Cary, NC: SAS Institute Inc; 2004.
27. Wyatt KM, Dimmock PW, O'Brien PM. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2002;4:CD001396.
28. Severino SK, Moline ML. Premenstrual Syndrome: A Clinician's Guide. New York: The Guilford Press; 1989.
29. Beck AT, Rush AJ, Shaw BF, et al. Cognitive Therapy of Depression. New York: Guilford Press; 1979.